- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03077685
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this open-label, dose-escalating, Phase IIa trial, subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Subjects will be enrolled in sequential cohorts of NanoPac® at escalating doses, at a volume based on up to 20% of calculated tumor volume (with a maximum injection volume of 5 mL per subject). Each cohort will have three subjects, with cohorts enrolled sequentially starting at the lowest concentration. Following DSMB review of the cohort data, the next cohort may begin enrolling, an additional three subjects at the current dose may be enrolled, or if the first dose does not provide adequate safety and tolerability the study may be halted.
The dose determined to be most suitable for further evaluation, defined as the highest dose with an acceptable safety and tolerability profile as determined by the Data Safety Monitoring Board (DSMB), will be the dose used in the second phase of the study which will enroll 22 additional subjects who will receive two injections of NanoPac® at the same dose one month apart. In the third phase of the study, up to 30 subjects will receive up to four injections of NanoPac at the same dose, one month apart.
Plasma samples will be taken at various time points on the day of NanoPac® injection as well as once at each of the study visits, to characterize the pharmacokinetics (PK) of intratumoral NanoPac®.
Subjects will be followed for 12 months after NanoPac® injection for safety, overall survival (OS), progression-free survival (PFS), CA-19-9 levels, carcinoembryonic antigen (CEA) levels, reduction in pain, and tumor response to therapy (as shown by imaging).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845
- Parkview Cancer Institute
-
-
Texas
-
El Paso, Texas, United States, 79905
- Texas Tech University Health Sciences Center
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent;
- Age ≥18 years;
- Histologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as documented via imaging (within 6 weeks of Screening);
- Subject not a candidate for surgery;
- Completion of at least one standard of care IV chemotherapy course for subjects in the dose escalation phase of the study. IV chemotherapy will be initiated prior to first NanoPac injection for subjects in the second and third phases. Hematologic recovery must be confirmed prior to study entry;
- Performance Status (ECOG) 0-1 at study entry;
- Life expectancy of at least 3 months;
Adequate marrow, liver, and renal function at study entry:
- ANC ≥ 1.5 x 109/L
- Hemoglobin ≥ 9.5 grams/dL
- Platelets ≥ 75 x 109/L
- Total bilirubin ≤ 1.5x institutional ULN
- AST/ ALT ≤ 2.5x institutional ULN
- Creatinine ≤ 1.5x institutional ULN
- Effective contraception if the risk of conception exists.
Exclusion Criteria:
- Thrombotic or embolic events;
- Acute or subacute intestinal occlusion;
- History of inflammatory bowel disease;
- Known hypersensitivity to study drugs;
- Known drug or alcohol abuse;
- Pregnant or breastfeeding women;
- Previous or concurrent history of non-pancreatic malignancy except for non-melanoma skin cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation: NanoPac® 6 mg/mL
Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
|
Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Other Names:
|
Experimental: Dose Escalation: NanoPac® 10 mg/mL
Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
|
Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Other Names:
|
Experimental: Dose Escalation: NanoPac® 15 mg/mL
Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
|
Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Other Names:
|
Experimental: Second Phase: NanoPac® at Best Dose
Intratumorally injected NanoPac® at a volume of up to 20% tumor volume.
The dose administered in the second phase will be determined during the dose escalation phase.
Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
|
Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Other Names:
|
Experimental: Third Phase: NanoPac® at Best Dose
Intratumorally injected NanoPac® at a volume of up to 20% tumor volume.
The dose administered in the third phase will be determined during the dose escalation phase.
Subjects will receive four NanoPac® administrations, with the injections administered one month apart.
|
Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment Emergent Adverse Events (safety and tolerability)
Time Frame: Up to 6 (six) months after NanoPac® injection
|
Treatment Emergent Adverse Events will include laboratory assessments, physical examination findings, and vital signs.
|
Up to 6 (six) months after NanoPac® injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) of NanoPac®
Time Frame: Up to 6 (six) months after NanoPac® injection
|
Pharmacokinetic (PK) samples will be taken on Day 1 prior to injection, and at 1, 2, 4, 6, and 24 hours post-injection, and again at all study visits post-injection
|
Up to 6 (six) months after NanoPac® injection
|
Pharmacokinetics: Peak plasma concentration (Cmax) of NanoPac®
Time Frame: Up to 6 (six) months after NanoPac® injection
|
Pharmacokinetic (PK) samples will be taken on Day 1 prior to injection, and at 1, 2, 4, 6, and 24 hours post-injection, and again at all study visits post-injection
|
Up to 6 (six) months after NanoPac® injection
|
Pharmacokinetics: Time at which peak plasma concentration is observed (Tmax) of NanoPac®
Time Frame: Up to 6 (six) months after NanoPac® injection
|
Pharmacokinetic (PK) samples will be taken on Day 1 prior to injection, and at 1, 2, 4, 6, and 24 hours post-injection, and again at all study visits post-injection
|
Up to 6 (six) months after NanoPac® injection
|
Tumor Response (RECIST)
Time Frame: Baseline and every 3 (three) months after NanoPac® injection, up to 12 months
|
Tumor burden at 3 months after NanoPac® injection will be compared with baseline tumor burden.
|
Baseline and every 3 (three) months after NanoPac® injection, up to 12 months
|
Change in pain score
Time Frame: Baseline and 3 (three) months after NanoPac® injection
|
Pain scores will be measured using a visual analog scale
|
Baseline and 3 (three) months after NanoPac® injection
|
Change in tumor markers
Time Frame: Baseline, 3 (three) months, and 6 (six) months after NanoPac® injection
|
Tumor markers measured will include CEA and CA19-9
|
Baseline, 3 (three) months, and 6 (six) months after NanoPac® injection
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Shelagh Verco, PhD, Vice President, Clinical Development, US Biotest, Inc
Publications and helpful links
General Publications
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
- Taxol® (paclitaxel) Injection Package Insert. Bristol-Myers Squibb Company. Rev July 2011.
- ABRAXANE Package Insert. Celgene Company. Rev July 2015.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NANOPAC-2016-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Pancreatic Adenocarcinoma
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterArcus Biosciences, Inc.SuspendedBorderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
TriSalus Life Sciences, Inc.RecruitingLocally Advanced Pancreatic AdenocarcinomaUnited States
-
Fuda Cancer Hospital, GuangzhouCompletedLocally Advanced Pancreatic AdenocarcinomaChina
-
National Cancer Institute (NCI)SuspendedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
UMC UtrechtRadboud University Medical Center; Catharina Ziekenhuis Eindhoven; Amsterdam... and other collaboratorsNot yet recruitingLocally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy (LAPSTAR)Locally Advanced Pancreatic AdenocarcinomaNetherlands
-
Impact Biotech LtdImpact biotech Ltd.Not yet recruitingLocally Advanced Unresectable Pancreatic Adenocarcinoma
-
Michael ChuongNovoCure Ltd.RecruitingPancreas Cancer | Locally Advanced Pancreatic Adenocarcinoma | Locally AdvancedUnited States
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingLocally Advanced Pancreatic AdenocarcinomaFrance
Clinical Trials on NanoPac®
-
NanOlogy, LLCUS Biotest, Inc.TerminatedOvarian CarcinomaUnited States
-
NanOlogy, LLCUS Biotest, Inc.CompletedPancreatic Mucinous-Cystic NeoplasmUnited States
-
NanOlogy, LLCUS Biotest, Inc.CompletedAdenocarcinoma of the ProstateUnited States
-
NanOlogy, LLCUS Biotest, Inc.Active, not recruitingLung Cancer | Lung Cancer, Nonsmall Cell | Neoplasm of Lung | Lung Cancer, Small CellUnited States
-
NanOlogy, LLCUS Biotest, Inc.TerminatedUrogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer AdenocarcinomaUnited States
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of